A new clinical trial will investigate whether a simple blood test could help detect breast cancer as early as Stage I.
|Videos|March 11, 2011
Dr. Pearlstone on Breast Cancer's 10 Year Progression
Author(s)David Pearlstone, MD
David Pearlstone, M.D. Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Breast Cancer's Surgical Progression in the Past 10 Years
Advertisement
David Pearlstone, M.D. Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Breast Cancer's Surgical Progression in the Past 10 Years
Advertisement
Related to this article
Phase 3 data showed a significant PFS improvement with trastuzumab pamirtecan vs chemotherapy in HR-positive, HER2-low metastatic breast cancer.
An exploratory TROPION-Breast02 analysis showed CNS PFS and intracranial response benefits with datopotamab deruxtecan in TNBC with brain metastases.
Abemaciclib plus fulvestrant showed a numerical yet nonsignificant overall survival trend after CDK4/6 inhibitor progression in final postMONARCH data.
Selective CDK4 inhibitor atirmociclib plus fulvestrant reduced risk of progression or death by 40% vs investigator's choice of therapy in the phase 2 FOURLIGHT-1 trial.
Signifcant efficacy improvements were shown with iza-bren in HR+/HER2-negative breast cancer.
A protein called MPP8 helps drive chemotherapy resistance in the most-aggressive subtype of breast cancer, and suppressing its expression has the potential to improve treatment outcomes.
Breast cancer experts address frequently asked questions on adjuvant and metastatic CDK4/6 inhibitor selection in HR-positive breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Receives BLA for Etentamig in R/R Multiple Myeloma
2
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
3
T-DXd Gains EU Approval in Residual HER2+ Early Breast Cancer
4
Elranatamab Meets Phase 3 PFS End Point in R/R Myeloma After Anti-CD38 Therapy and Lenalidomide
5